{"name":"Regeneron","slug":"regeneron","ticker":"REGN","exchange":"NASDAQ","domain":"regeneron.com","description":"Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.","hq":"Tarrytown, NY","founded":0,"employees":"15410","ceo":"Leonard S. Schleifer","sector":"Large Biotech","stockPrice":768.29,"stockChange":8.02,"stockChangePercent":1.05,"marketCap":"$81.2B","metrics":{"revenue":26080000000,"revenueGrowth":2.5,"grossMargin":44.6,"rdSpend":5850200000,"netIncome":4504900000,"cash":8605200384,"dividendYield":0.49,"peRatio":18.5,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Dupixent","genericName":"DUPILUMAB","slug":"dupilumab","revenue":14600000000,"yoyGrowth":0,"percentOfTotal":56},{"name":"Vegf Trap","genericName":"AFLIBERCEPT","slug":"aflibercept","revenue":9800000000,"yoyGrowth":0,"percentOfTotal":37.6},{"name":"Libtayo","genericName":"CEMIPLIMAB","slug":"cemiplimab","revenue":1452000000,"yoyGrowth":0,"percentOfTotal":5.6},{"name":"Inmazeb","genericName":"MAFTIVIMAB","slug":"maftivimab","revenue":76000000,"yoyGrowth":0,"percentOfTotal":0.3},{"name":"Inmazeb","genericName":"ODESIVIMAB","slug":"odesivimab","revenue":76000000,"yoyGrowth":0,"percentOfTotal":0.3},{"name":"Inmazeb","genericName":"ATOLTIVIMAB","slug":"atoltivimab","revenue":76000000,"yoyGrowth":0,"percentOfTotal":0.3}],"timeline":[{"date":"2008-01-01","label":"Arcalyst first approved","drug":"Arcalyst","drugSlug":"rilonacept","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Vegf Trap first approved","drug":"Vegf Trap","drugSlug":"aflibercept","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Dupixent first approved","drug":"Dupixent","drugSlug":"dupilumab","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Libtayo first approved","drug":"Libtayo","drugSlug":"cemiplimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Inmazeb first approved","drug":"Inmazeb","drugSlug":"maftivimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Inmazeb first approved","drug":"Inmazeb","drugSlug":"odesivimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Inmazeb first approved","drug":"Inmazeb","drugSlug":"atoltivimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"IMDEVIMAB first approved","drug":"IMDEVIMAB","drugSlug":"imdevimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ronapreve first approved","drug":"Ronapreve","drugSlug":"casirivimab","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Evkeeza first approved","drug":"Evkeeza","drugSlug":"evinacumab","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Veopoz first approved","drug":"Veopoz","drugSlug":"pozelimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-01","label":"Eylea patent cliff ($2.5B at risk)","drug":"Eylea","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Dupixent patent cliff ($10.5B at risk)","drug":"Dupixent","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":14600000000,"percentOfTotal":56,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dupixent","genericName":"DUPILUMAB","slug":"dupilumab","indication":"Asthma","status":"marketed","revenue":14600000000}]},{"name":"Oncology","slug":"oncology","revenue":11252000000,"percentOfTotal":43.1,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Vegf Trap","genericName":"AFLIBERCEPT","slug":"aflibercept","indication":"Branch retinal vein occlusion with macular edema","status":"marketed","revenue":9800000000},{"name":"Libtayo","genericName":"CEMIPLIMAB","slug":"cemiplimab","indication":"Malignant tumor of cervix","status":"marketed","revenue":1452000000}]},{"name":"Other","slug":"other","revenue":228000000,"percentOfTotal":0.9,"drugCount":11,"colorKey":"cardiovascular","drugs":[{"name":"Inmazeb","genericName":"MAFTIVIMAB","slug":"maftivimab","indication":"Ebola virus disease","status":"marketed","revenue":76000000},{"name":"Inmazeb","genericName":"ODESIVIMAB","slug":"odesivimab","indication":"Ebola virus disease","status":"marketed","revenue":76000000},{"name":"Inmazeb","genericName":"ATOLTIVIMAB","slug":"atoltivimab","indication":"Ebola virus disease","status":"marketed","revenue":76000000},{"name":"ALN-SNCA","genericName":"ALN-SNCA","slug":"aln-snca","indication":"Other","status":"phase_1"},{"name":"Apixiban","genericName":"Apixiban","slug":"apixiban","indication":"Other","status":"phase_2"},{"name":"Arcalyst","genericName":"RILONACEPT","slug":"rilonacept","indication":"Cryopyrin associated periodic syndrome","status":"marketed"},{"name":"Fasinumab AI","genericName":"Fasinumab AI","slug":"fasinumab-ai","indication":"Other","status":"phase_1"},{"name":"Noninterventional","genericName":"Noninterventional","slug":"noninterventional","indication":"Other","status":"phase_2"},{"name":"REGN5837","genericName":"REGN5837","slug":"regn5837","indication":"Other","status":"phase_1"},{"name":"VEOPOZ","genericName":"POZELIMAB-BBFG","slug":"pozelimab-bbfg","indication":"CD55-deficient PLE (CHAPLE disease)","status":"marketed"},{"name":"Veopoz","genericName":"POZELIMAB","slug":"pozelimab","indication":"CHAPLE disease","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"EVKEEZA","genericName":"EVINACUMAB-DGNB","slug":"evinacumab-dgnb","indication":"Homozygous familial hypercholesterolemia","status":"marketed"},{"name":"Evkeeza","genericName":"EVINACUMAB","slug":"evinacumab","indication":"Homozygous familial hypercholesterolemia","status":"marketed"},{"name":"Praluent","genericName":"Praluent","slug":"praluent","indication":"Atherosclerosis","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"IMDEVIMAB","genericName":"IMDEVIMAB","slug":"imdevimab","indication":"COVID-19","status":"discontinued"},{"name":"Ronapreve","genericName":"CASIRIVIMAB","slug":"casirivimab","indication":"COVID-19","status":"marketed"}]}],"pipeline":[{"name":"Dupixent","genericName":"DUPILUMAB","slug":"dupilumab","phase":"marketed","mechanism":"Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response.","indications":["Asthma","Atopic dermatitis","Chronic sinusitis","Eosinophilic esophagitis","Prurigo nodularis"],"catalyst":""},{"name":"Vegf Trap","genericName":"AFLIBERCEPT","slug":"aflibercept","phase":"marketed","mechanism":"Vascular endothelial growth factor A","indications":["Branch retinal vein occlusion with macular edema","Central retinal vein occlusion with macular edema","Exudative age-related macular degeneration","Macular edema due to diabetes mellitus","Metastasis from malignant tumor of colon"],"catalyst":""},{"name":"Libtayo","genericName":"CEMIPLIMAB","slug":"cemiplimab","phase":"marketed","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.","indications":["Malignant tumor of cervix","Metastatic basal cell carcinoma","Non-small cell lung cancer without mutation in epidermal growth factor receptor","Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","Squamous cell carcinoma"],"catalyst":""},{"name":"Inmazeb","genericName":"MAFTIVIMAB","slug":"maftivimab","phase":"marketed","mechanism":"Inmazeb works by binding to and neutralizing the Ebola virus.","indications":["Ebola virus disease"],"catalyst":""},{"name":"Inmazeb","genericName":"ODESIVIMAB","slug":"odesivimab","phase":"marketed","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells.","indications":["Ebola virus disease"],"catalyst":""},{"name":"Inmazeb","genericName":"ATOLTIVIMAB","slug":"atoltivimab","phase":"marketed","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells and thereby reducing the severity of the disease.","indications":["Ebola virus disease"],"catalyst":""},{"name":"ALN-SNCA","genericName":"ALN-SNCA","slug":"aln-snca","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apixiban","genericName":"Apixiban","slug":"apixiban","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Arcalyst","genericName":"RILONACEPT","slug":"rilonacept","phase":"marketed","mechanism":"Arcalyst works by binding to Interleukin-1 beta, preventing its interaction with its receptor and reducing inflammation.","indications":["Cryopyrin associated periodic syndrome"],"catalyst":""},{"name":"EVKEEZA","genericName":"EVINACUMAB-DGNB","slug":"evinacumab-dgnb","phase":"marketed","mechanism":"Angiopoietin-related protein 3","indications":["Homozygous familial hypercholesterolemia"],"catalyst":""},{"name":"Evkeeza","genericName":"EVINACUMAB","slug":"evinacumab","phase":"marketed","mechanism":"Evkeeza works by blocking the action of Angiopoietin-related protein 3, a protein that helps regulate cholesterol levels in the blood.","indications":["Homozygous familial hypercholesterolemia"],"catalyst":""},{"name":"Fasinumab AI","genericName":"Fasinumab AI","slug":"fasinumab-ai","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IMDEVIMAB","genericName":"IMDEVIMAB","slug":"imdevimab","phase":"discontinued","mechanism":"IMDEVIMAB works by binding to the SARS-CoV-2 virus to prevent it from entering host cells.","indications":["COVID-19"],"catalyst":""},{"name":"Noninterventional","genericName":"Noninterventional","slug":"noninterventional","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Praluent","genericName":"Praluent","slug":"praluent","phase":"marketed","mechanism":"Proprotein convertase subtilisin/kexin type 9","indications":["Atherosclerosis","Complex dyslipidemia","Familial hypercholesterolemia - heterozygous","Hypercholesterolemia"],"catalyst":""},{"name":"REGN5837","genericName":"REGN5837","slug":"regn5837","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ronapreve","genericName":"CASIRIVIMAB","slug":"casirivimab","phase":"marketed","mechanism":"Monoclonal antibody","indications":["COVID-19"],"catalyst":""},{"name":"VEOPOZ","genericName":"POZELIMAB-BBFG","slug":"pozelimab-bbfg","phase":"marketed","mechanism":"Pozelimab-bbfg blocks C5 cleavage, preventing C5a and C5b formation and inhibiting terminal complement activation.","indications":["CD55-deficient PLE (CHAPLE disease)"],"catalyst":""},{"name":"Veopoz","genericName":"POZELIMAB","slug":"pozelimab","phase":"marketed","mechanism":"Veopoz works by blocking the activity of Complement C5, a protein that contributes to inflammation.","indications":["CHAPLE disease"],"catalyst":""}],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Regeneron Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results","summary":"Regeneron reported fourth-quarter and full-year 2023 financial results, with net sales of $7.4 billion and $28.5 billion, respectively.","drugName":"","sentiment":"positive"},{"date":"2023-12-22","type":"deal","headline":"Regeneron and Sanofi Announce Collaboration to Develop and Commercialize New Cancer Therapies","summary":"Regeneron and Sanofi announced a collaboration to develop and commercialize new cancer therapies, with Regeneron contributing its cancer-focused pipeline and Sanofi providing its expertise in oncology.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"regulatory","headline":"FDA Approves Libtayo for First-Line Treatment of Basal Cell Carcinoma","summary":"The FDA approved Libtayo for the first-line treatment of basal cell carcinoma, expanding its indication to include this type of skin cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQQ3pRanZSNnFwUlRrc0llOVBHejRFTHA5RHotT0VkQzhhWXRscGFZdVlVQy1kYVlBc1VSczdOaGppUjJ6Sk9ILVlCUlJuVkJ2N3NETG1YOTNYM0hvM0pIckVHVFBnS3UxQkZXLVNCcG1wc2ZTbDE5eDI0OGt6ajNqMFFrNlJIOUFMWmxJNUxjbUt2YWc1VW1LTi1mQ0R5QlpiUjBWeUoxcE05Rkp1V1JDTTlBVHU0eEk2aEZvYzYtMnhhZW5LaVp3WHJJUTRoNENsaG5jWGFZTE5KWDcyX2IzVldB?oc=5","date":"2026-04-08","type":"pipeline","source":"MarketBeat","summary":"Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat","headline":"Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN","sentiment":"neutral"},{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"regulatory","source":"simplywall.st","summary":"Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals - simplywall.st","headline":"Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"MSN","summary":"Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN","headline":"Where is Regeneron Pharmaceuticals (REGN) headed according to analysts?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOd0NxaGNSZ3NtRjdHUmRISlliRHBBaldPdkk3MzhHb3BEcWwxZTA5VVBKbmVzaEJrTDlyS1pUclVTVTdNaWF3aHFQaHowVThCWGxlR29GYklBYzN1UnFHTDRYVUh0dkdtWFBLSFlMY3dSdThZd21PWWJTd2p5cG5OZllvdXVmUjJwaG13eTVVdlEtQmN3VU9fQ1dhbVNheUlWbmxYRXU0VGJhLXR4MEdvS2hmQWthUFlYRkRlUHJpQmhSd0dZODZoM3RGVms4WTZ6UHc?oc=5","date":"2026-04-05","type":"deal","source":"MarketBeat","summary":"2,145 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Perpetual Ltd - MarketBeat","headline":"2,145 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Perpetual Ltd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPOW8tVG16aS1wc1RZRUFsczJ5LVNwdFg5X0RVcl8wQ1RKOHdYWnNTUGVGdUlId2lwZHFTUFVGbWU4YVZpcm03aGdjLThMd0JfNWpTb25iMFlPaWNYb3I5UDJURGhBZ2xIVzZOQ1hxRGMzakpIb2paSk1OeXMtZFk2U2VGT2Q5UjR3YlRwZlA4TjFnZTNvdXZ3THNGREhubV9QU3M1WGk5dmptUHg0SFdKbFBaZ29BYVdla2xuMGJLR2JFNVFUdmEyanNn?oc=5","date":"2026-04-05","type":"pipeline","source":"MarketBeat","summary":"Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC - MarketBeat","headline":"Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNN2dPM0lvTWhPZlZGSUlYaExucjg5NEJza2I4YXA0UktJaS1RaW03a2ZPbHJJdXhDamlXWGtoa2xPc3cyS1NBcXJ4a0MxMEVBX09FYXR3YVBsQ0t3SVBNYjB3WWFISnp4QldXSGRrQ0FKUVpIeExaMjdMRU84ODdtdWlpNzVRcmg0b3NQYjBBWXNUOS03c1k2OHFJNFpDTXhwdjBhS3RRaTEtODhVM3gzMVZpNVZ6ZlBXTUNWNXp1YkZVd1VYQThMcDVWZmtxY0Q0SS1XMVJWZTMzMXFaRXZxVFlBdmZ4SlQxY2J2Y0ZHUE5KdUI1VDdIMlpSZ1QxTnFpVzE2Wnd4VEFwZjBqNE9SS2tfcEk0Qk41LUdmempZaVRrUjZzMkh3VUlLUVY0Qkd4cmdSY0hYVExJaGV5dW9Ndk9qdWpkVjVWaHROLVM1ZkFENGI5Ymc?oc=5","date":"2026-04-04","type":"pipeline","source":"MSN","summary":"Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock - MSN","headline":"Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdkhkdnpoYnBoTE9zSXZxeFFvM0dxT053bnQyMENyekwtX3hxbHFFV1l0Y2lGX09BNDhoQlNvc2VMRnFVUTFuaEo4X1VBbHBfZlhYX3prRWgyb1h2VTluVDN0S3dLVnJJTXNQc1J1ZHdIR24tajZ3N1QzWElwMGhvRlA4akNxa19VS0tDM1BDLVBxZDZZZFJYY0VQRi00SVlmbDBmcG1LM1ZGQndPbng3Yi1mVVh3aENYOFhxS19yaUhKYm8?oc=5","date":"2026-04-02","type":"pipeline","source":"Reuters","summary":"Regeneron says it expects to avoid new US pharma tariffs - Reuters","headline":"Regeneron says it expects to avoid new US pharma tariffs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-31","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Regeneron (REGN) After Its Mixed Share Price Performance? - simplywall.st","headline":"Is It Time To Reassess Regeneron (REGN) After Its Mixed Share Price Performance?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPcEYyY3RIOVZac2ROTnZ5eW9zUXNyUEVyaHZkQWFzWFpOTnFnT1RuNGJBOEtKcnZ6amRUc1BRX2tPN1Z5a09HWVRjU2lwQnlES0RKYmE3M1JIcWdFTGltX2E0TzNfb2ZTSlJfYjJLR29iRUlZMTNyMzk2VktEWUN1bkJMWDcwWDJXMlk5Qm1JTkV1eXNuODMwUDFmeHFGb05XakFBVFV6VHJWYjRMNTdKUjVjTDg?oc=5","date":"2026-03-31","type":"regulatory","source":"Yahoo Finance","summary":"A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid - Yahoo Finance","headline":"A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNSkt2TzVEOHJvTmlRQkl1cXdybEVnT0hGN0pZQ0EzblJoY0N4SUN2NGM0NUI2ZmNwUXJzaXdoMzVfT3RxUzNLVWpBVHRFRlNDU0htRFIzWmZ1UUZEU3kyN2VBTjBZTTh3bTgxaVVOZk1ZT1VYOENHSHc2eGc4YXhqUndENmZHSll5blRZSEZDN2R1Z1BLV3J6OUJfN0hTYzN5bFBZ?oc=5","date":"2026-03-30","type":"pipeline","source":"Yahoo Finance","summary":"Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock - Yahoo Finance","headline":"Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQdmZOOS0yR1l2dlRRVGh2RXZoZmdpZHRlWElna0h5TXg0RzJXcXR3OXBZZlhHVDlRckFyX2E1VGlac2JvcTlsZWNoRUVtZkd4T1hrZ1pJU0ZrTzJtUW5MSW1pd2VoTDBaREdlc3lneGZvTFpyd0k0VFRGbUM3dmhDSUNfZ285SVJUd0hEamp2OHE0MjVXRWZoMQ?oc=5","date":"2026-03-30","type":"pipeline","source":"The Motley Fool","summary":"Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena - The Motley Fool","headline":"Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNYWptSHdpRjhGTll4aWRVa3FRcGxSaklOQ0dKRVJuN2FHTElkMEtCbXltNE1RbDRDTTB4VzVkWGJoWVNSV3l0RXJ1Wlo5RlotUFd6alZsVU55QkV3anRFZEp4YWlsd3VsTXlQV3U0eGxDRkFuTzA4N3Y1ZVBpQ1Q2Y2dPVktfbHFfdWxuRzdB?oc=5","date":"2026-03-15","type":"deal","source":"Yahoo Finance","summary":"Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy? - Yahoo Finance","headline":"Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?","sentiment":"neutral"},{"date":"2026-02-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-01-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Eylea","drugSlug":"aflibercept","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Dupixent","drugSlug":"dupilumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":10500000000}],"drugCount":19,"phaseCounts":{"marketed":13,"phase_1":3,"phase_2":2,"discontinued":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Amgen","Roche Holding"],"therapeuticFocus":["Eye Diseases","Cancer","Infectious Diseases"],"financials":{"source":"sec_edgar","revenue":5872227000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":5872227000,"period":"2017-12-31"},{"value":1582447000,"period":"2017-12-31"},{"value":1500673000,"period":"2017-09-30"},{"value":1470116000,"period":"2017-06-30"},{"value":1318991000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5850200000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":4504900000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":40558700000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":768.29,"previousClose":760.27,"fiftyTwoWeekHigh":821.11,"fiftyTwoWeekLow":476.49,"fiftyTwoWeekRange":"476.49 - 821.11","fiftyDayAverage":765.65,"twoHundredDayAverage":663.99,"beta":0.4,"enterpriseValue":72386256896,"forwardPE":14.6,"priceToBook":2.52,"priceToSales":5.66,"enterpriseToRevenue":5.05,"enterpriseToEbitda":17.05,"pegRatio":1.63,"ebitda":4245700096,"ebitdaMargin":29.6,"freeCashflow":3258374912,"operatingCashflow":4978899968,"totalDebt":2972699904,"debtToEquity":9.5,"currentRatio":4.13,"returnOnAssets":5.9,"returnOnEquity":14.9,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":28,"targetMeanPrice":873.2,"targetHighPrice":1057,"targetLowPrice":730,"dividendRate":3.76,"payoutRatio":0.08,"fiveYearAvgDividendYield":0,"exDividendDate":1771545600,"insiderHeldPercent":2,"institutionHeldPercent":90.8,"sharesOutstanding":103902660,"floatShares":98554009,"sharesShort":2451498,"shortRatio":4.04,"shortPercentOfFloat":2.3,"epsTrailing":41.51,"epsForward":52.6,"revenuePerShare":137.12,"bookValue":304.65,"officers":[{"age":72,"name":"Dr. Leonard S. Schleifer M.D., Ph.D.","title":"Co-Founder, President, CEO & Co-Chairman"},{"age":65,"name":"Dr. George D. Yancopoulos M.D., Ph.D.","title":"Co-Founder, President, Chief Scientific Officer & Co-Chairman"},{"age":54,"name":"Mr. Christopher R. Fenimore CPA","title":"Executive VP of Finance & CFO"},{"age":66,"name":"Dr. Andrew J. Murphy Ph.D.","title":"Executive VP of Research & Co-Chief Scientific Officer"},{"age":52,"name":"Mr. Daniel P. Van Plew","title":"Executive VP and GM of Industrial Operations & Product Supply"},{"age":null,"name":"Mr. Rajesh  Ahuja","title":"Senior Vice President of Quality Assurance & Operations"},{"age":null,"name":"Mr. Ryan  Steinberger","title":"Executive VP, Chief Digital & Technology Officer"},{"age":null,"name":"Mr. Ryan  Crowe","title":"Senior Vice President of Investor Relations & Strategic Analysis"}],"industry":"Biotechnology","irWebsite":"http://newsroom.regeneron.com/","website":"https://www.regeneron.com","phone":"914 847 7000"}}